Cumplido-Trasmonte, C.
Ramos-Rojas, J.
Delgado-Castillejo, E.
Garcés-Castellote, E.
Puyuelo-Quintana, G.
Destarac-Eguizabal, M. A.
Barquín-Santos, E.
Plaza-Flores, A.
Hernández-Melero, M.
Gutiérrez-Ayala, A.
Martínez-Moreno, M.
García-Armada, E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effects of ATLAS 2030 gait exoskeleton on strength and range of motion in children with spinal muscular atrophy II: a case series
https://doi.org/10.1186/s12984-022-01055-x
Funding for this research was provided by:
Consejería de Educación e Investigación de la Comunidad de Madrid (PEJ-2019-AI_TIC-15202, IND2017_TIC-7698)
Comunidad de Madrid (IND2018/TIC9618, IND2017_TIC-7698)
Ministry of Science and Innovation (DI-16-08731, PTQ2018-010119)
Article History
Received: 24 March 2022
Accepted: 6 July 2022
First Online: 19 July 2022
Declarations
:
: This study was performed in accordance with the Declaration of Helsinki [CitationRef removed], approval was obtained (reference 47/370329.9/19) by Comunidad de Madrid Regional Research Ethics and the clinical trial has been registered on Clinical Trials.gov: NCT04837157.
: Written informed consent for publication has been given by parents or legal guardians of involved patients.
: G-Ar is a founder and promoter of Marsi Bionics which produces ATLAS exoskeleton. P-Q, G-C, D-E, B-S and P-F work for Marsi Bionics and receive a salary for this work. The remaining authors have no conflicts of interest to declare.